Samuraciclib (CT7001) Managed Access Policy

Carrick Therapeutics is building an innovative portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer. In doing so, we aim to have a major impact on the lives of patients with the greatest unmet need and transform the way cancer is treated.

At this time Carrick Therapeutics is conducting clinical trials to evaluate the safety and effectiveness of our investigational drug, Samuraciclib (CT7001). Once sufficient positive data is available from clinical trials, Carrick Therapeutics plans to submit the data to regulatory authorities (such as the FDA and EMA) to obtain marketing approval so that Samuraciclib can be made available to any patient who needs it.

At the current time, Carrick Therapeutics is not making Samuraciclib available on a managed access basis (for example expanded access, compassionate use, named patient supply) outside of a clinical trial setting. This is because the evaluation of the safety and effectiveness of Samuraciclib is still at an early stage of clinical development and until sufficient data is available, Carrick Therapeutics must exercise due care in making Samuraciclib available on any managed access basis.

Carrick Therapeutics continuously monitors emerging data from our clinical trials. When the data is advanced enough to enable an assessment of the potential benefit and risks of use outside a clinical trial setting, Carrick Therapeutics will further consider facilitating managed access at that time.

The most up to date information regarding our ongoing Samuraciclib (CT7001) clinical trials is available at www.clinicaltrials.gov by searching ‘CT7001’.